Marisa Wexler, MS,  senior science writer—

The PAH Initiative is hosting a video event in May to provide information about the benefits of exercise for people with pulmonary arterial hypertension (PAH). “The Power of Movement: Cardiopulmonary Rehabilitation for PAH” is part of the initiative’s PAH Today national broadcast series. Lana Melendres-Groves, MD, director of…

The advocacy organization Phaware is launching a series of podcasts to explore new advances in the treatment of pulmonary hypertension associated with interstitial lung disease (PH-ILD). The series will be launched as part of “I’m Aware That I’m Rare: the phaware podcast,” which can be found online…

Treatment with the approved therapy Winrevair (sotatercept-csrk) significantly reduced the risk of death, lung transplant, or hospitalization in people with pulmonary arterial hypertension (PAH), according to results from the Phase 3 ZENITH clinical trial. Findings were published in The New England Journal of Medicine, in the study, “…

The U.S. Food and Drug Administration (FDA) is poised to soon issue a final determination on Yutrepia, an inhaled dry powder formulation of treprostinil, up for approval to treat both pulmonary hypertension associated with interstitial lung disease (PH-ILD) and pulmonary arterial hypertension (PAH). The FDA granted Yutrepia…

People with coarctation of aorta, or COA — a condition marked by narrowing where the body’s largest blood vessel connects to the heart — are at high risk of developing pulmonary hypertension (PH), and this risk increases as time goes on, a study showed. The data also showed that…

Merck announced that its Phase 3 clinical trial HYPERION, which had been testing Winrevair (sotatercept-csrk) in people with recently diagnosed pulmonary arterial hypertension (PAH), will be ended early — a move that will allow all study participants, including those who had been assigned to receive a placebo,…

An imaging technique called 18F-FAPI PET may be able to detect the earliest signs of changes in blood vessel tissues that occur in pulmonary arterial hypertension (PAH), a new study reports. According to researchers, this novel approach, which uses positron emission tomography or PET imaging, may help…

Using in-depth analyses and machine learning, scientists have identified several molecules and genes involved in metabolism that may be diagnostic markers of pulmonary arterial hypertension (PAH). Specifically, their research found five small molecules, or metabolites, and three metabolism-related genes that are tied to a PAH diagnosis. All were “identified…

Sildenafil is generally more effective than bosentan at controlling blood pressure and reducing the need for supplemental oxygen in infants with persistent pulmonary hypertension of the newborn (PPHN), a study shows. The study, “Oral sildenafil versus bosentan for treatment of persistent pulmonary hypertension of the newborn:…

High levels of a small RNA molecule in the blood may be a marker of pulmonary arterial hypertension (PAH) in people with congenital heart diseases, a new study reveals. The study, “Expression and Diagnostic Value of miR-3591-5p in Patients with Congenital Heart Disease-Associated Pulmonary Arterial Hypertension,”…

A Phase 2 clinical trial of TX45, Tectonic Therapeutic’s investigational therapy for pulmonary hypertension and heart failure with preserved ejection fraction (PH-HFpEF), has begun enrolling eligible patients. The Phase 2 study, called APEX (NCT06616974), is expected to recruit up to 180 adults with PH-HFpEF, ages…

Adding Uptravi (selexipag) to standard-of-care therapy within six months of starting treatment may reduce the risk of hospitalization and disease progression in people with pulmonary arterial hypertension (PAH), a study found. The study, “Early Addition of Selexipag to Double Therapy for Pulmonary Arterial Hypertension,” was…